Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

International Flavors & Fragrances Inc. (IFF) SEC Filings & Earnings Calls

EquiReason read 12 International Flavors & Fragrances Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — IFF reported Q2 2026 results: sales +2% reported (+6% comparable currency neutral), gross margin +80bps, operating profit +11%, and announced $2.5B share repurchase authorization..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

IFFInternational Flavors & Fragrances Inc.Follow IFF — free
Specialty Chemicals · Basic Materials
—
Price chart with a free account
Market cap
24.0B
P/E TTM
82.6
Dividend yield
1.7%
52-week
—
Next earnings
3 Nov, in 10 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

4 Aug 202610-QIFF reported Q2 2026 results: sales +2% reported (+6% comparable currency neutral), gross margin +80bps, operating profit +11%, and announced $2.5B share repurchase authorization.earningsopen

Figures in the filing · each found in the filing text

Net sales · Q2-2026$1.95B+2% y/y
Gross margin · Q2-202643.7%
Operating profit · Q2-2026$158M+11% y/y
Operating cash flow · H1-2026$679M+85% y/y
Capital expenditure · H1-2026$301M

Guidance

Capital spending expected to be approximately 6.0% of total company sales in 2026, up from approximately 5.5% in 2025

Management reaffirmed outlook with capex guidance increase to 6.0% of sales, indicating confidence in demand and investment.

Risks flagged

Regulatory costs pressure

“The increase in S&A expenses was primarily driven by higher incentive compensation expense and regulatory costs.” · word for word

Divestiture execution risk

“On May 29, 2026, we announced that we entered into a definitive agreement to divest our Food Ingredients disposal group.” · word for word
Read the original on SEC EDGAR ↗
4 Aug 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen

Risks flagged

Divestiture execution risk; regulatory approvals needed.

“Closing subject to regulatory approvals and customary conditions.”
Read the original on SEC EDGAR ↗
4 Aug 20268-K · 2.02, 8.01Sales $1.95B (+2% y/y); Adjusted Operating EBITDA $408M; Adjusted Operating EBITDA Margin 20.9; Guidance: Full year 2026 guidance on continuing ops basisearningsopen

Figures in the filing · each found in the filing text

Sales · continuing_operations · Q2-2026$1.95B+2% y/y
Adjusted Operating EBITDA · continuing_operations · Q2-2026$408M
Adjusted Operating EBITDA Margin · continuing_operations · Q2-202620.9%

Guidance

Full year 2026 guidance on continuing ops basis

Guidance consistent with previous; underlying performance unchanged.

Risks flagged

Divestiture execution risk; stranded cost elimination needed.

“Stranded costs to be eliminated; regulatory approvals pending.”
Read the original on SEC EDGAR ↗
23 Jun 20268-K · 1.01, 2.03IFF entered a $1B senior unsecured delayed draw term loan facility to refinance €800M notes due Sep 2026, with mandatory prepayment from Food Ingredients sale proceeds (~$3.8B).SEC ↗
1 Jun 20268-K · 1.01, 8.01IFF entered a Transaction Agreement on May 29, 2026, disclosed via press release in Item 8.01. No further details on nature or value.SEC ↗
5 May 202610-QNet sales $2.74B (-4% y/y); Gross margin 37.1; Adjusted Operating EBITDA margin 20.7; Guidance: capex guided to ~6% of sales in 2026 vs 5.5% in 2025open

Figures in the filing · each found in the filing text

Net sales · Q1-2026$2.74B-4% y/y
Gross margin · Q1-202637.1%
Adjusted Operating EBITDA margin · Q1-202620.7%
Operating cash flow · Q1-2026$257M+102% y/y

Guidance

capex guided to ~6% of sales in 2026 vs 5.5% in 2025

No explicit revenue or margin guidance; capex guidance indicates increased investment; management tone is positive based on volume growth and productivity gains.

Risks flagged

Scent segment pricing pressure

“On a comparable currency neutral basis, Scent Segment Adjusted Operating EBITDA decreased 2% in 2026 compared to the prior year period as unfavorable net pricing more than offset volume increases.” · word for word

Divestiture execution risk

“Losses on business disposals were $7 million in the first quarter of 2026. The loss in 2026 was due to the SCL disposal group business divestiture.” · word for word
Read the original on SEC EDGAR ↗
5 May 20268-K · 2.02Net sales $2.74B (-4% y/y); Adjusted operating EBITDA $568M; Adjusted EPS excluding amortization $1.25; Guidance: Sales guidance $10.5B-$10.8Bearningsopen

Figures in the filing · each found in the filing text

Net sales · Q1-2026$2.74B-4% y/y
Adjusted operating EBITDA · Q1-2026$568M
Adjusted EPS excluding amortization · Q1-2026$1.25
Free cash flow · Q1-2026$92M

Guidance

Sales guidance $10.5B-$10.8B

Reaffirmed full-year 2026 guidance, citing solid Q1 results and derisking of balance of year.

Risks flagged

Uncertain operating environment may impact future performance; Scent segment EBITDA declined due to unfavorable price to input cost.

“Scent adjusted operating EBITDA decreased (2)% as volume growth and productivity gains were more than offset by unfavorable price to input cost.”
Read the original on SEC EDGAR ↗
18 Mar 2026DEF 14AIFF filed its 2026 proxy statement, disclosing 2025 compensation, governance updates, and a clawback of $606,280 due to an accounting restatementopen

Figures in the filing · each found in the filing text

Net Sales · FY2025$10.90B
Operating Loss · FY2025$-382M
Adjusted Operating EBITDA · FY2025$2.10B
Diluted EPS · FY2025$-1.41
Adjusted Diluted EPS · FY2025$2.52
Adjusted Diluted EPS ex Amortization · FY2025$4.20
Net Debt to Credit Adjusted EBITDA · FY2025$2.60
Share Repurchase Authorization · FY2025$500M
Currency Neutral Sales Growth · FY20252.0%
Currency Neutral Adjusted Operating EBITDA Growth · FY20257.0%

Risks flagged

Accounting restatement risk

“Management identified certain adjustments that primarily relate to the understatement of income tax expense due to errors in the accounting for transfer pricing, the correction of deferred tax liabilities on goodwill recorded in purchase accounting, and other income tax entries that impacted prior interim and annual financial statements” · word for word

Goodwill impairment risk

“The 2025 Net Loss of $361 million reflects a goodwill impairment charge of $1.153 Billion”

Portfolio execution risk

“the Company commenced an evaluation of strategic alternatives for the Food Ingredients business” · word for word
Read the original on SEC EDGAR ↗
27 Feb 202610-KNet sales $10.89B (-5% y/y); Gross profit $3.94B (-5% y/y); Gross margin 36.2; Guidance: Capital spending expected to be approximately 6% of sales in 2026open

Figures in the filing · each found in the filing text

Net sales · FY2025$10.89B-5% y/y
Gross profit · FY2025$3.94B-5% y/y
Gross margin · FY202536.2%
Net income (loss) attributable to IFF shareholders · FY2025$-361M-237% y/y
Operating cash flow · FY2025$850M-21% y/y
Goodwill impairment · Food Ingredients · FY2025$1.15B
Capital spending as % of sales (guidance) · FY20266.0%

Guidance

Capital spending expected to be approximately 6% of sales in 2026

No explicit revenue or margin guidance; capex guidance provided; management tone appears positive based on volume growth and margin improvement.

Risks flagged

Goodwill impairment risk

“we determined that the carrying value of the Food Ingredients reporting unit exceeded its fair value and recorded an impairment charge of $1.153 billion.” · word for word

Divestiture execution risk

“We completed the divestiture of our Pharma Solutions disposal group ... on May 1, 2025 and we divested our nitrocellulose business ... on May 9, 2025.” · word for word

Raw material cost volatility

“Our products rely on both natural and synthetic ingredients.” · word for word
Read the original on SEC EDGAR ↗
11 Feb 20268-K · 2.02Net sales $10.89B (-5% y/y); Adjusted operating EBITDA $2.09B (+7% y/y); Adjusted EPS excluding amortization $4.20earningsopen

Figures in the filing · each found in the filing text

Net sales · FY2025$10.89B-5% y/y
Adjusted operating EBITDA · FY2025$2.09B+7% y/y
Adjusted EPS excluding amortization · FY2025$4.20
Cash flow from operations · FY2025$850M
Free cash flow · FY2025$256M
Taste segment sales · Taste · FY2025$2.48B+2% y/y
Health & Biosciences segment sales · Health & Biosciences · FY2025$2.28B+4% y/y
Scent segment sales · Scent · FY2025$2.48B+2% y/y
Food Ingredients segment sales · Food Ingredients · FY2025$3.28B-3% y/y
Reported loss before taxes · FY2025$-412M

Risks flagged

Macroeconomic uncertainty persists, potentially impacting demand.

“While macroeconomic uncertainty persists, we are encouraged by the strength of our pipeline” · word for word

Food Ingredients segment under pressure from Protein Solutions softness and low-margin business exit.

“Food Ingredients ... comparable currency neutral sales decreased (3)% as double-digit growth in Inclusions was offset primarily by softness in Protein Solutions as well as the proactive exit of low margin business”
Read the original on SEC EDGAR ↗
4 Nov 20258-K · 2.02Sales $2.69B (-8% y/y); Income before taxes $56M; EPS $0.16earningsopen

Figures in the filing · each found in the filing text

Sales · Q3-2025$2.69B-8% y/y
Income before taxes · Q3-2025$56M
EPS · Q3-2025$0.16
Adjusted operating EBITDA · Q3-2025$519M
Adjusted operating EBITDA margin · Q3-202519.3%
EPS ex amortization · Q3-2025$1.05
Cash flows from operations (9 months) · 9M-2025$532M
Free cash flow (9 months) · 9M-2025$126M

Guidance

Reaffirms full year 2025 guidance despite 'more challenging operating environment'; margin expansion driven by productivity

Risks flagged

Tough operating environment, short-term pressures in Health & Biosciences and Food Ingredients, sales decline 8% reported

Read the original on SEC EDGAR ↗
4 Nov 202510-QIFF reported Q3 2025 net sales of $2.694B (-8% reported, flat comparable currency neutral), gross margin +50bps, and completed divestitures of Pharma Solutions and Nitrocellulose.earningsopen

Figures in the filing · each found in the filing text

Net sales · Consolidated · Q3-2025$2.69B-8% y/y
Gross margin · Consolidated · Q3-202536.5%
Net income (loss) attributable to IFF shareholders · Consolidated · Q3-2025$40M-31% y/y
Cash and cash equivalents · Consolidated · 2025-09-30$621M
Free cash flow (operating) · Consolidated · 9M-2025$532M-22% y/y

Risks flagged

Goodwill impairment risk

“The impairment of goodwill was $1.153 billion in the first nine months of 2025 compared to $64 million in the 2024 period.” · word for word

Divestiture execution risk

“Loss on assets classified as held for sale was $108 million in Q3 2025 related to Soy Crush, Concentrates & Lecithin business.” · word for word

Leverage and debt covenant risk

“Our Revolving Credit Agreement states that from the effective date through September 30, 2025, our net debt to credit adjusted EBITDA ratio shall not exceed 4.00x, and shall not exceed 3.75x thereafter.”
Read the original on SEC EDGAR ↗

International Flavors & Fragrances Inc. — questions

What did International Flavors & Fragrances Inc. file recently?
12 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — IFF reported Q2 2026 results: sales +2% reported (+6% comparable currency neutral), gross margin +80bps, operating profit +11%, and announced $2.5B share repurchase authorization.

Every figure on this page comes from International Flavors & Fragrances Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.